AZR Azora Therapeutics, Inc. (DE)

AZR financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1513525 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 12, 2026 Data checked: Nov 13, 2026
Showing 3 of 9 annual and 0 of 37 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$6.48M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
434-422-9800
EIN
800667150
Headquarters
ENCINO, CA, 91436
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: ADIAL PHARMACEUTICALS, INC. (2017–2026) · Adial Pharmaceuticals, L.L.C. (2017–2017) · ADial Pharmaceuticals, L.L.C. (2017–2017)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
-
Net Income
$-120.57M
Total Assets
$22.53M
Total Equity
$-21.06M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
572.5%
Return on Assets
-535.2%
Current Ratio
4.43x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, Azora Therapeutics, Inc. (DE) reported net loss of $7.98M. Diluted earnings per share were -$11.93, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 668.63K links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Diluted shares moved 244.5% from 194.06K in fiscal 2024, leaving the current share base higher year over year. Total assets stood at $6.67M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

Operations produced a $7.80M operating loss before non-operating and tax effects. The company ended the period with a net loss of $7.98M, extending the operating result through all remaining items. Before income taxes, the company recorded a loss of $7.98M, bridging the operating result to the final net loss. The loss-to-equity relationship was 151.2%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 119.5%, placing the bottom-line deficit against the company’s resource base. The net loss narrowed to $7.98M from $13.20M in fiscal 2024.

Liquidity and Capital Structure

At period end, the $6.67M asset base was financed through $1.40M of liabilities and $5.28M of equity. Current assets were $6.18M against $1.40M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 4.42x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $5.88M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 421.0% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled 79.1% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 20.9%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 88.1% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 32.3% higher than fiscal 2024 assets of $5.04M, measuring the company’s own balance-sheet change. Book equity was 29.7% higher than fiscal 2024 equity of $4.07M, showing how shareholder capital changed year over year. The reported cash balance changed 56.8% from $3.75M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $6.49M, rather than cash generation from operations. Cash absorbed by operations decreased from $6.92M in fiscal 2024 to $6.49M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Azora Therapeutics, Inc. (DE)
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $2.62M $3.23M $1.27M
SG&A Expense $5.18M $5.06M $5.62M
Operating Income $-7.80M $-8.28M $-6.89M
NON-OPERATING INCOME / EXPENSE
Interest Income $149.57K $178.66K $69.78K
Other Income/Expense $164.85K $-75.04K $10.16K
Pretax Income $-7.98M $-13.20M $-7.00M
Net Income $-7.98M $-13.20M $-5.12M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-11.93 $-68.01 $-90.00
Diluted Shares 668.63K 194.06K 56.99K
Balance Sheet
ASSETS
Cash & Equivalents $5.88M $3.75M $2.83M
Other Current Assets $299.67K $308.24K $371.60K
Current Assets $6.18M $4.06M $3.20M
Intangible Assets $2.78K $3.35K $3.91K
Noncurrent Assets $492.48K $985.18K $1.54M
Total Assets $6.67M $5.04M $4.74M
LIABILITIES
Accounts Payable $655.21K $250.13K $103.33K
Other Current Liabilities $77.50K - -
Current Liabilities $1.40M $975.86K $653.08K
Noncurrent Liabilities $0 $0 $0
Total Liabilities $1.40M $975.86K $653.08K
EQUITY
Common Stock $1.11K $259 $1.66K
Additional Paid-in Capital $95.25M $86.06M $72.88M
Retained Earnings $-89.97M $-82.00M $-68.80M
Total Equity $5.28M $4.07M $4.08M
Total Liabilities & Equity $6.67M $5.04M $4.74M
SUPPLEMENTAL
Shares Outstanding 1.11M 258.83K 66.54K
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-6.49M $-6.92M $-6.81M
Capital Expenditures - - -
Cash from Investing $150.00K $0 $1.50M
Cash from Financing $8.47M $7.85M $4.13M
Free Cash Flow - - -
Beginning Cash (CFS) $3.75M $2.83M $4.00M
Net Change in Cash $2.13M $923.44K $-1.17M
Effect of FX on Cash - - -
Calculated Ending Cash $5.88M $3.75M $2.83M
Cash per BS $5.88M $3.75M $2.83M
Cash scope difference (CFS − BS) - - -
Cash per CFS $5.88M $3.75M $2.83M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is Azora Therapeutics, Inc. (DE) profitable?

No. Azora Therapeutics, Inc. (DE) reported $-120.57M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.